DRUG AFFINITY

Question 1

HOW MUCH OF THE HUMAN GENOME IS DISEASE CAUSING

Answer 1

10%

Question 2

IF A PROTEIN HAS A ‘POCKET’ IN WHICH A SMALL MOLECULE CAN FIT, WHAT CAN WE DO

Answer 2

TARGET THE PROTEIN WITH DRUGS

Question 3

DEFINE DRUGS

Answer 3

SMALL MOLECULES THAT TARGET PROTEINS

Question 4

WHAT TYPES OF TARGET PROTEINS ARE THERE

Answer 4

1. RECEPTORS
2. ION CHANNELS
3. ENZYMES
4. TRANSPORTERS
5. OTHER TARGETS SUCH AS MICROTUBULES

Question 5

WHAT CAN BE SAID ABOUT THE SPECIFICITY OF DRUGS

Answer 5

NO DRUG IS 100% SPECIFIC

Question 6

HOW CAN RECEPTORS BE CLASSIFIED

Answer 6

1. STRUCTURE
2. PHARMACEUTICAL PROPERTIES
3. SIGNALLING

Question 7

WHAT IS AN AGONIST

Answer 7

BRING ABOUT CELL FUNCTION CHANGE (DIRECT/INDIRECT)

Question 8

WHAT IS AN ANTAGONIST

Answer 8

BIND TO A RECEPTOR STOPPING ACTIVATION AND DISALLOWING OTHER AGONISTS TO BIND

Question 9

WHAT IS AN INVERSE AGONIST

Answer 9

BIND TO RECEPTOR STOPPING ACTIVATION

Question 10

WHAT EFFECTS CAN SMALL MOLECULES HAVE ON CHANNELS

Answer 10

1. BLOCKERS

2. MODULATORS

Question 11

IN TERMS OF ENZYMES AND TRANSPORTERS, HOW CAN THEY BE AFFECTED

Answer 11

1. INHIBITORS CAN BIND TO PREVENT FUNCTION
2. FALSE SUBTRATES CREATE ABNORMAL METABOLITES
3. PRO DRUGS METABOLISED TO CREATE THE ACTUAL ACTIVE DRUG

Question 12

WHAT ARE THE RECEPTOR FAMILIES

Answer 12

1. LIGAND GATED ION CHANNELS (IONOTROPIC)
2. GPCR (METABOTROPIC)
3. KINASE LINKED
4. NUCLEAR

Question 13

WHAT MAIN TYPES OF LIGAND GATED ION CHANNELS ARE THERE

Answer 13

1. CYS LOOP
2. GLUTAMATE
3. P2X
4. CA RELEASE

Question 14

HOW MANY TMSD DO GPCR HAVE

Answer 14

7

Question 15

HOW MANY TMSD DO NUCLEAR RECEPTORS HAVE

Answer 15

NONE AS THEY ARE IN THE NUCLEUS AND NOT IN THE BILAYER

Question 16

WHAT TYPE OF BINDING DOMAIN TO NUCLEAR RECEPTORS HAVE

Answer 16

DNA BINDING (ZINC FINGERS)